



Solenio Therapeutics to Participate in Two Upcoming Investor Conferences

March 11, 2019

REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Solenio Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel titled, "*How Will Orphan & Ultra-Orphan Drugs Stand up Against Pricing Uncertainties?*", and provide a corporate update, at the 31st Annual ROTH Conference, taking place March 17-19, 2019, in Dana Point, CA.

Dr. Bhatnagar will also present a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking place March 19-20, 2019, in New York, NY. The presentation will take place on Wednesday, March 20, at 10:55 AM ET, and will be webcast live at <https://www.veracast.com/webcasts/opco/healthcare2019/04207604863.cfm>.

About Solenio Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit www.solenio.life.

CONTACT:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Source: Solenio Therapeutics